Colgate-Palmolive Company (“Colgate”) and Klox Technologies Inc. (“Klox”) have entered into agreements to globally commercialize and further develop Klox’s human oral health technology platform. The agreements include a worldwide license to commercialize Klox’s proprietary biophotonic technology in the field of human oral health and an equity investment in Klox by Colgate.
Dr. Lise Hébert, president and CEO of Klox, stated: “We are extremely pleased to have Colgate-Palmolive, the leader in oral care, with activities in over 200 countries and territories, be our global partner for our oral health platform. These agreements once again recognize the breadth of our technology platform. Furthermore, these agreements validate the value creation strategy we have adopted by partnering large potential indications with first in class partners, while building a specialized sales force for products within wound care.”
According to its website, Klox is “a specialty pharmaceutical company focusing on the development and commercialization of its proprietary BioPhotonic technology platform. This non-invasive, pathology-specific topical treatment platform harnesses the power of light and photo-activated, oxygen-rich gel formulations to target various skin and soft tissue disorders.”
Suzan Harrison, president of Global Oral Care of Colgate, stated: “We are very pleased to have Klox as a partner in the development of this exciting and new technology platform for the benefit of oral health.”
About Klox Technologies Inc.:
Klox is a specialty pharmaceutical company focused on developing and commercializing products based on its proprietary biophotonic technology platform to address skin and soft-tissue disorders. The company has a multifranchise platform focusing on indications across dermatology, wound care, and oral health. To learn more about Klox, please visit http://www.kloxtechnologies.com.